Year-end Sale % OFF 
Abstract
The BIOFLOW V trial demonstrated a lower rate of target lesion failure (TLF) at 12 months in patients treated with the ultrathin strut, biodegradable polymer sirolimus-eluting stent (BP SES) compared to a thin strut, durable polymer everolimus-eluting stent (DP EES). The difference in TLF was driven
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
